期刊
DRUG INFORMATION JOURNAL
卷 42, 期 3, 页码 223-233出版社
DRUG INFORMATION ASSOC
DOI: 10.1177/009286150804200304
关键词
-
In this article, we review quantitative measures that have been proposed to conduct comparative benefit:risk assessment. Comparative benefit:risk assessment could be conducted at the societal level (recommending drug approval or the adoption of a medical policy) or at the individual level (making a treatment selection). Benefit:risk assessment involves balancing between benefit and risk. The need to make decisions based on all information forces us to think diligently on the trade-off between benefit and risk in a structured manner. Even though we discuss measures to facilitate benefit:risk assessment in this article, we want to remind the readers that it cannot replace the rigorous assessment of efficacy and safety individually. Rather, it complements the traditionally separate safety and efficacy analysis by bringing safety and efficacy assessment together in a unified approach.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据